research Advance Understanding and New Treatment of Alopecia Areata
New treatments for the autoimmune hair loss condition alopecia areata may include JAK inhibitors and other immunomodulators.
Search
for
Sort by
Research
150-180 / 1000+ results
research New Treatment Strategies in Management of Alopecia Areata: Review Article
New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.
research Alopecia Areata: Current Review
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
research 원형탈모증(alopecia areata)의 최신 이해와 치료
New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.
research Revisión y avances en tricología
Recent advancements in hair loss treatments include new therapies and insights for different types of alopecia.
research INVESTIGATING THE MECHANISMS UNDERLYING THE PATHOGENESIS OF ALOPECIA AREATA
Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.
research 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
IL-15 helps maintain hair growth and protects the immune status of hair follicles.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
research Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
research Current and future pharmacotherapy for alopecia areata
New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
research SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
research Pharmacological Treatment of Alopecia
Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
research Forging the Future: 2018 Alopecia Areata Research Summit Summary Report
The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
research Skin cancer risk in alopecia areata: a systematic review and meta-analysis
Alopecia areata may lower melanoma risk and does not increase overall skin cancer risk.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research A transcriptomic map of murine and human alopecia areata
Alopecia areata involves specific immune cells, offering potential treatment targets.
research Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
research Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
research Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RNAseq Analysis
Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium
COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
research Free Papers Medical and Surgical: Hair and Nails
The document discusses hair and nail conditions, updates on treatments for alopecia, and controversies around finasteride use.
research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
research ZNF750 safeguards upper hair follicle homeostasis to prevent inflammatory skin disease
ZNF750 helps keep hair follicles healthy and prevents skin inflammation.
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
research Vitiligo—Current Treatment Options and Future Perspectives
Vitiligo treatment is improving with new drugs and therapies, focusing on personalized and combined approaches.
research 496 Identification of differentially expressed miRNAs in alopecia areata that target immune-regulatory pathways
Researchers found that certain miRNAs, which affect immune system regulation, are differently expressed in mice with a hair loss condition compared to healthy mice.